IS6845A - Pýridasínón aldósa afsýringarkljúfshindrar - Google Patents

Pýridasínón aldósa afsýringarkljúfshindrar

Info

Publication number
IS6845A
IS6845A IS6845A IS6845A IS6845A IS 6845 A IS6845 A IS 6845A IS 6845 A IS6845 A IS 6845A IS 6845 A IS6845 A IS 6845A IS 6845 A IS6845 A IS 6845A
Authority
IS
Iceland
Prior art keywords
antacids
pyridazinone aldose
pyridazinone
aldose
aldose antacids
Prior art date
Application number
IS6845A
Other languages
English (en)
Other versions
IS2205B (is
Inventor
Lakshman Mylari Banavara
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS6845A publication Critical patent/IS6845A/is
Publication of IS2205B publication Critical patent/IS2205B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS6845A 2001-03-30 2003-06-16 Pýridasínón aldósa afsýringarkljúfshindrar IS2205B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28005101P 2001-03-30 2001-03-30
PCT/IB2002/000320 WO2002079198A1 (en) 2001-03-30 2002-01-31 Pyridazinone aldose reductase inhibitors

Publications (2)

Publication Number Publication Date
IS6845A true IS6845A (is) 2003-06-16
IS2205B IS2205B (is) 2007-02-15

Family

ID=23071435

Family Applications (3)

Application Number Title Priority Date Filing Date
IS6845A IS2205B (is) 2001-03-30 2003-06-16 Pýridasínón aldósa afsýringarkljúfshindrar
IS8250A IS8250A (is) 2001-03-30 2006-01-23 Pýridasínón aldósa afsýringarkljúfshindrar
IS8251A IS8251A (is) 2001-03-30 2006-01-23 Pýridasínón aldósa afsýringarkljúfshindrar

Family Applications After (2)

Application Number Title Priority Date Filing Date
IS8250A IS8250A (is) 2001-03-30 2006-01-23 Pýridasínón aldósa afsýringarkljúfshindrar
IS8251A IS8251A (is) 2001-03-30 2006-01-23 Pýridasínón aldósa afsýringarkljúfshindrar

Country Status (44)

Country Link
US (2) US6579879B2 (is)
EP (3) EP1491541B1 (is)
JP (1) JP2004528319A (is)
KR (1) KR100586138B1 (is)
CN (1) CN1215067C (is)
AP (1) AP2002002461A0 (is)
AR (1) AR035798A1 (is)
AT (3) ATE348100T1 (is)
AU (1) AU2002226634B2 (is)
BG (1) BG108179A (is)
BR (1) BR0208571A (is)
CA (1) CA2442476A1 (is)
CZ (1) CZ20032563A3 (is)
DE (3) DE60202452C5 (is)
DK (2) DK1491540T3 (is)
EA (1) EA006023B1 (is)
EC (1) ECSP034671A (is)
EE (1) EE200300470A (is)
ES (2) ES2231681T3 (is)
GE (1) GEP20053675B (is)
HK (1) HK1061678A1 (is)
HR (1) HRP20030752A2 (is)
HU (1) HUP0303644A3 (is)
IL (1) IL156462A0 (is)
IS (3) IS2205B (is)
MA (1) MA27003A1 (is)
MX (1) MXPA03008850A (is)
MY (1) MY134304A (is)
NO (1) NO20034345D0 (is)
NZ (1) NZ528406A (is)
OA (1) OA12453A (is)
PA (1) PA8541801A1 (is)
PE (1) PE20030007A1 (is)
PL (1) PL365294A1 (is)
PT (2) PT1491540E (is)
SI (1) SI1373259T1 (is)
SK (1) SK11852003A3 (is)
TN (1) TNSN02037A1 (is)
TW (1) TWI245762B (is)
UA (1) UA73236C2 (is)
UY (1) UY27237A1 (is)
WO (1) WO2002079198A1 (is)
YU (1) YU71403A (is)
ZA (1) ZA200304671B (is)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
ES2240657T3 (es) * 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
ES2231681T3 (es) * 2001-03-30 2005-05-16 Pfizer Products Inc. Inhibidores de piridazinona de la aldosa reductasa.
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
CN1269814C (zh) * 2002-01-09 2006-08-16 辉瑞产品公司 哒嗪酮抗糖尿病药的制备方法和中间体
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006028565A2 (en) * 2004-06-30 2006-03-16 Whitehead Institute For Biomedical Research Novel methods for high-throughput genome-wide location analysis
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CA2636007A1 (en) * 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
RU2444521C2 (ru) 2006-06-27 2012-03-10 Такеда Фармасьютикал Компани Лимитед Конденсированные циклические соединения
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
MX355015B (es) * 2011-09-15 2018-04-02 Univ Taipei Medical Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal.
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CA2982784A1 (en) * 2015-04-14 2016-10-20 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
DK3757107T3 (da) 2016-06-21 2023-11-27 Univ Columbia 4-oxo-3,4-dihydrothieno[3,4-d]pyridazinforbindelser som aldosereduktasehæmmere og metoder til anvendelse deraf
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
AU2018215678A1 (en) 2017-02-06 2019-08-22 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
CA3071114A1 (en) 2017-07-28 2019-01-31 Applied Therapeutics Inc. Compositions and methods for treating galactosemia
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها
MX2021014443A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
CN114502540A (zh) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 Tead抑制剂和其用途
WO2022120353A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
EP0516860A4 (en) * 1990-11-30 1993-12-01 Tsumura & Co. Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
WO1992017446A2 (en) 1991-03-28 1992-10-15 Pfizer Inc. Pyridazinone acetic acids aldose reductase inhibitors
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR20010015607A (ko) * 1997-09-24 2001-02-26 에사 헤이노넨, 마자 리타라 포스폴암밴 억제자로서 1-옥사, 아자 및티아나프탈렌-2-온의 비스에테르
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
ES2231681T3 (es) * 2001-03-30 2005-05-16 Pfizer Products Inc. Inhibidores de piridazinona de la aldosa reductasa.
KR20040015199A (ko) * 2001-04-30 2004-02-18 화이자 프로덕츠 인크. 알도스 환원효소 억제제 및 시클로옥시게나제-2 억제제의조합
CN1269814C (zh) * 2002-01-09 2006-08-16 辉瑞产品公司 哒嗪酮抗糖尿病药的制备方法和中间体

Also Published As

Publication number Publication date
US6849629B2 (en) 2005-02-01
NO20034345L (no) 2003-09-29
DE60217930T2 (de) 2007-10-18
DE60216823D1 (de) 2007-01-25
MXPA03008850A (es) 2003-12-04
HUP0303644A3 (en) 2008-06-30
DE60217930D1 (de) 2007-03-15
KR20030088484A (ko) 2003-11-19
CZ20032563A3 (cs) 2004-05-12
GEP20053675B (en) 2005-11-25
US6579879B2 (en) 2003-06-17
SK11852003A3 (sk) 2004-07-07
ATE352551T1 (de) 2007-02-15
IS8251A (is) 2006-01-23
DE60202452T2 (de) 2006-02-09
DE60216823T2 (de) 2007-10-04
DK1491540T3 (da) 2007-03-26
EA006023B1 (ru) 2005-08-25
PT1373259E (pt) 2005-03-31
DE60202452C5 (de) 2006-11-23
YU71403A (sh) 2006-05-25
PL365294A1 (en) 2004-12-27
US20030162784A1 (en) 2003-08-28
ES2231681T3 (es) 2005-05-16
HRP20030752A2 (en) 2005-06-30
PE20030007A1 (es) 2003-01-28
BR0208571A (pt) 2004-03-23
IS8250A (is) 2006-01-23
ZA200304671B (en) 2004-06-25
AR035798A1 (es) 2004-07-14
EP1373259A1 (en) 2004-01-02
DK1373259T3 (da) 2005-03-29
EE200300470A (et) 2004-02-16
PA8541801A1 (es) 2002-10-28
MA27003A1 (fr) 2004-12-20
EP1491540B1 (en) 2006-12-13
EP1491540A1 (en) 2004-12-29
BG108179A (en) 2004-09-30
AP2002002461A0 (en) 2002-06-30
HK1061678A1 (en) 2004-09-30
ES2274369T3 (es) 2007-05-16
ATE348100T1 (de) 2007-01-15
EP1491541A1 (en) 2004-12-29
CN1500087A (zh) 2004-05-26
NO20034345D0 (no) 2003-09-29
TNSN02037A1 (fr) 2005-12-23
UA73236C2 (en) 2005-06-15
AU2002226634B2 (en) 2007-01-25
ATE286049T1 (de) 2005-01-15
ECSP034671A (es) 2003-08-29
IL156462A0 (en) 2004-01-04
KR100586138B1 (ko) 2006-06-07
JP2004528319A (ja) 2004-09-16
DE60202452D1 (de) 2005-02-03
CN1215067C (zh) 2005-08-17
EP1491541B1 (en) 2007-01-24
EP1373259B1 (en) 2004-12-29
IS2205B (is) 2007-02-15
EA200300673A1 (ru) 2003-12-25
MY134304A (en) 2007-12-31
OA12453A (en) 2006-05-24
HUP0303644A2 (hu) 2004-03-01
PT1491540E (pt) 2007-01-31
SI1373259T1 (en) 2005-04-30
UY27237A1 (es) 2002-12-31
TWI245762B (en) 2005-12-21
CA2442476A1 (en) 2002-10-10
NZ528406A (en) 2004-03-26
US20020143017A1 (en) 2002-10-03
WO2002079198A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
IS8250A (is) Pýridasínón aldósa afsýringarkljúfshindrar
DE60212857D1 (de) Thermischer schnappschalter
DK1361880T3 (da) 6-substituerede pyrido-pyrimidiner
PT1411764E (pt) Cerca
DE60207168D1 (de) Lüftungsanlage
NO20042742L (no) Pyrimidinforbindelser
NO20031562D0 (no) Vinterdekk
DE60216425D1 (de) Ausgleichswellenzusammenbau
DE60126833D1 (de) Flugzeugsitzkonstruktion
DE60210848D1 (de) Verbinder
DE50200795D1 (de) Mikroventil
DE60221366D1 (de) Verbinder
DE50210548D1 (de) Spannbaugruppe
DE60233695D1 (de) Verbinder
DE50206864D1 (de) Spoiler-Fahrzeugdach
DE50108179D1 (de) Verbinder
DE60231053D1 (de) Stirlingmaschinenzusammenbau
ATE405973T1 (de) Steckverbindung
ES1050823Y (es) Casco salvavidas
FI5142U1 (fi) Jänisräikkä
UA5367S (uk) Навіс
FI20011758A0 (fi) Henkilökohtainen virtsauslaite
NO20010670D0 (no) SMS pengeinnsamling
FI5472U1 (fi) Puhelaite
ITNU20010002U1 (it) Idroespulsore ii